Filing Flows › Sight Sciences (SGHT) › Q2 2026
Sight Sciences (SGHT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Sight Sciences (SGHT) reported revenue of $23.4M for the second quarter 2026 (Q2 2026), +20% from a year earlier and +19% from the quarter before. Operating margin was -16.6%, net loss $4.4M (19.0% of revenue).
Sight Sciences, Q2 2026: revenue $23.4M (+20% year over year), operating margin -16.6%, net loss $4.4M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.4M | +19% | +20% |
| Operating profit | −$3.9M | — | — |
| Net earnings | −$4.4M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $23.4M in Q2 2026, up 20% year over year and up 19% from the previous quarter. Surgical Glaucoma was the largest line at 89% of revenue. Dry Eye added $2.3M year over year (up 703%), 61% of the total change.
Gross margin was 91.4%, up 6.6 points from Q2 2025. Operating costs exceeded revenue by $3.9M, an operating margin of -16.6%. Operating expenses fell 11% while revenue rose 20%. The quarter ended with a net loss of $4.4M, narrower than the previous quarter's $13.0M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $94K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $4.3M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$5.7M.
Questions
What was Sight Sciences' revenue in the second quarter 2026?
Sight Sciences (SGHT) reported revenue of $23.4M for the second quarter 2026 (Q2 2026), +20% from a year earlier and +19% from the quarter before.
Was Sight Sciences profitable in the second quarter 2026?
Operating loss was $3.9M (-16.6% of revenue) and net loss $4.4M.
Source: Sight Sciences 10-Q on SEC EDGAR.